Several RCTs (21, 22) and a meta-analysis (23) have demonstrated that the use of SGLT2 inhibitors lowers cardiovascular mortality and reduces hospitalizations due to HF in patients irrespective of the presence of diabetes. Here, SLC5A2 is linked to hydrops fetalis.